Transplant Proc . Recovery of Moderate Coronavirus Disease 2019 in a Liver Transplant Recipient on Continued Immunosuppression: A Case Report

[tetano]

Transplant Proc


. 2020 Sep 17;S0041-1345(20)32742-1.
doi: 10.1016/j.transproceed.2020.09.007. Online ahead of print.
Recovery of Moderate Coronavirus Disease 2019 in a Liver Transplant Recipient on Continued Immunosuppression: A Case Report


Victor Dahl Mathiasen ¹ , Stine Karlsen Oversoe ² , Peter Ott ² , S?ren Jensen-Fangel ³ , Steffen Leth ³



Affiliations

• PMID: 33039144
• PMCID: PMC7498236
• DOI: 10.1016/j.transproceed.2020.09.007

Free PMC article

Abstract

The global outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had an enormous impact on the world. Owing to limited data available, it remains unclear to what extent liver transplant recipients should be considered at a higher risk of severe disease. We describe a moderate course of coronavirus disease 2019 (COVID-19) in a patient who underwent a liver transplant 2 years earlier because of Budd-Chiari syndrome. The patient presented with malaise, headache, dry cough, and fever for 4 days. Immunosuppressive therapy with tacrolimus and mycophenolate mofetil was continued throughout the course of infection. Oxygen therapy was given for a single night, and the patient gradually recovered with supportive care only. With this case report, we demonstrate that liver transplantation and immunosuppression is not necessarily associated with severe COVID-19 and emphasize that more information on this matter is urgently required. Withdrawal of immunosuppressive therapy could be associated with higher mortality.